Moleculin Biotech Inc. has announced that it received a notification from the Nasdaq Stock Market LLC regarding its non-compliance with the Nasdaq Listing Rule 5550(b)(1). This rule requires companies to maintain a minimum of $2.5 million in stockholders' equity. As of May 23, 2025, Moleculin Biotech does not meet this requirement, nor does it fulfill alternative criteria related to market value of listed securities or net income from continuing operations. While this notification does not immediately affect the company's listing status on the Nasdaq Capital Market, Moleculin Biotech has 45 days to submit a compliance plan. If accepted, the company could be granted an extension of up to 180 days to meet the necessary requirements. Failure to have the plan accepted could lead to an appeal process, though success is not guaranteed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。